RE: A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen

Cancer Cell

Volumn 6, Issue 5, 2004, Pages 445-

  Sgroi, Dennis C ^a   Haber, Daniel A ^a   Ryan, Paula D ^a   Ma, Xiao Jun ^b   Erlander, Mark G ^b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b Harvard Medical School ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; CLINICAL TRIAL; COHORT ANALYSIS; DRUG EFFICACY; GENE EXPRESSION PROFILING; HUMAN; LETTER; LYMPH NODE METASTASIS; PREDICTION; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR VOLUME;

EID: 7944235406     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2004.11.001     Document Type: Letter

References (2)

1. Ma X.J., Wang Z., Ryan P.D., Isakoff S.J., Barmettler A., Fuller A., Muir B., Mohapatra G., Salunga R., Tuggle J.T., et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell. 5:2004;607-616
2. EBCTCG (Early Breast Cancer Trialists' Collaborative Group). Tamoxifen for early breast cancer. An overview of the randomized trials Lancet. 351:1998;1451-1467